

Study title: Molecular imaging before and during (chemo-) radiotherapy in patients with locally advanced Head and Neck, thoracic and pelvic tumors: prognostic and predictive value of 18F-fluoro-azomycin arabinoside-PET/CT in head and neck squamous cell carcinoma.

Date	Our reference	Page
9 May 2022		1 of 1
Your reference	Contact	
2015-005278-40	Michel.deGroot@radboudumc.nl	

Subject

**Posting of clinical trial results in EudraCT**

Dear Sir, Dear Madam,

Above referenced clinical trial has ended prematurely due to (s)low patient recruitment and logistical challenges during the course of the trial. Therefore, publication of results is deemed not feasible. For recruited subjects, no safety issues or (S)AE's were identified.

Yours sincerely,



*Michel de Groot, clinical research coordinator  
Radboud University Medical Center  
Dept. Of Medical Imaging, Nuclear Medicine, IP 756  
Geert Grooteplein Zuid 10  
6525 GA NIJMEGEN  
The Netherlands  
Tel. 024-3667243*

**Radboud university medical center**

Radiology and Nuclear Medicine

Location Nuclear Medicine

P.O. Box 9101, 6500 HB Nijmegen

The Netherlands

Internal postal code 756

Geert Grooteplein Zuid 10

Radboudumc Main entrance, route 756

T +31 24 14048

F +31 24 18942

Head of Department

M. Prokop, Prof.

[www.radboudumc.nl/rng](http://www.radboudumc.nl/rng)

Dutch Chamber of Commerce

trade register 80262783